By Professor Michael Leonard Friedlander

Journal articles

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky M-C; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075

Chiang JCB; Goldstein D; Tavakoli A; Trinh T; Klisser J; Lewis CR; Friedlander M; Naduvilath TJ; Au K; Park SB; Krishnan AV; Markoulli M, 2021, 'Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel', Scientific Reports, 11, pp. 22884, http://dx.doi.org/10.1038/s41598-021-02439-0

Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 1721 - 1731, http://dx.doi.org/10.1016/S1470-2045(21)00531-3

Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M, 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, 163, pp. 524 - 530, http://dx.doi.org/10.1016/j.ygyno.2021.09.010

Kehm RD; MacInnis RJ; John EM; Liao Y; Kurian AW; Genkinger JM; Knight JA; Colonna SV; Chung WK; Milne R; Zeinomar N; Dite GS; Southey MC; Giles GG; McLachlan SA; Whitaker KD; Friedlander ML; Weideman PC; Glendon G; Nesci S; Phillips KA; Andrulis IL; Buys SS; Daly MB; Hopper JL; Terry MB, 2021, 'Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkab090

Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V, 2021, 'Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial', Therapeutic Advances in Medical Oncology, 13, http://dx.doi.org/10.1177/17588359211059601

Conduit C; Milne RL; Friedlander ML; Phillips KA, 2021, 'Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence', Cancer Prevention Research, 14, pp. 983 - 994, http://dx.doi.org/10.1158/1940-6207.CAPR-21-0141

Campbell R; King MT; Ross TL; Cohen PA; Friedlander ML; Webb PM, 2021, 'Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment', Gynecologic Oncology, 163, pp. 398 - 407, http://dx.doi.org/10.1016/j.ygyno.2021.08.022

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Alsadius D; Pretre V; Han Y; Matulonis U, 2021, 'EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 31, pp. A139 - A140, http://dx.doi.org/10.1136/ijgc-2021-IGCS.350

Park HA; Neumeyer S; Michailidou K; Bolla MK; Wang Q; Dennis J; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baten A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Brauch H; Brenner H; Brucker SY; Burwinkel B; Campa D; Canzian F; Castelao JE; Chanock SJ; Chenevix-Trench G; Clarke CL; Børresen-Dale AL; Grenaker Alnæs GI; Sahlberg KK; Ottestad L; Kåresen R; Schlichting E; Holmen MM; Sauer T; Haakensen V; Engebråten O; Naume B; Fosså A; Kiserud CE; Reinertsen KV; Helland Å; Riis M; Geisler J; Conroy DM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Engel C; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grip M; Guénel P; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Han S; Harkness EF; Hart SN; He W; Heemskerk-Gerritsen BAM; Hopper JL; Hunter DJ; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham D; Sachchithananthan M, 2021, 'Mendelian randomisation study of smoking exposure in relation to breast cancer risk', British Journal of Cancer, 125, pp. 1135 - 1145, http://dx.doi.org/10.1038/s41416-021-01432-8

Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M, 2021, 'A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial', Gynecologic Oncology, 163, pp. 72 - 78, http://dx.doi.org/10.1016/j.ygyno.2021.07.024

Berek JS; Renz M; Kehoe S; Kumar L; Friedlander M, 2021, 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', International Journal of Gynecology and Obstetrics, 155, pp. 61 - 85, http://dx.doi.org/10.1002/ijgo.13878

Colombo N; Moore K; Scambia G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Kim JW; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2021, 'Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial', Gynecologic Oncology, 163, pp. 41 - 49, http://dx.doi.org/10.1016/j.ygyno.2021.07.016

Puhalla SL; Diéras V; Arun BK; Kaufman B; Wildiers H; Han HS; Ayoub JP; Stearns V; Yuan Y; Helsten T; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak CK; Ramathal CY; Friedlander M, 2021, 'Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin/paclitaxel for gBRCA advanced breast cancer (BROCADE3 Crossover)', Clinical Cancer Research, 27, pp. 4983 - 4993, http://dx.doi.org/10.1158/1078-0432.CCR-21-0748

Scott F; Smet ME; Hardy T; Sundercombe S; Friedlander M; Carey L; Kirk E; Li B; McLennan A, 2021, 'Concurrent maternal malignancy and fetal trisomy detected using genome-wide noninvasive prenatal screening', Prenatal Diagnosis, 41, pp. 1273 - 1276, http://dx.doi.org/10.1002/pd.6020

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bell-McGuinn KM; Bach BA; Kundu MG; Ratajczak CK; Maag D; Diéras V, 2021, 'Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial', European Journal of Cancer, 154, pp. 35 - 45, http://dx.doi.org/10.1016/j.ejca.2021.05.037

Quinn MCJ; McCue K; Shi W; Johnatty SE; Beesley J; Civitarese A; O'Mara TA; Glubb DM; Tyrer JP; Armasu SM; Ong JS; Gharahkhani P; Lu Y; Gao B; Patch AM; Fasching PA; Beckmann MW; Lambrechts D; Vergote I; Velez Edwards DR; Beeghly-Fadiel A; Benitez J; Garcia MJ; Goodman MT; Dörk T; Dürst M; Modugno F; Moysich K; Du Bois A; Pfisterer J; Bauman K; Karlan BY; Lester J; Cunningham JM; Larson MC; McCauley BM; Kjaer SK; Jensen A; Hogdall CK; Hogdall E; Schildkraut JM; Riggan MJ; Berchuck A; Cramer DW; Terry KL; Bjorge L; Webb PM; Friedlander M; Pejovic T; Moffitt M; Glasspool R; May T; Ene GEV; Huntsman DG; Woo M; Carney ME; Hinsley S; Heitz F; Fereday S; Kennedy CJ; Edwards SL; Winham SJ; DeFazio A; Pharoah PDP; Goode EL; MacGregor S; Chenevix-Trench G, 2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, 76, pp. 535 - 536, http://dx.doi.org/10.1097/OGX.0000000000000962

Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK, 2021, 'Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy', European Journal of Cancer, 154, pp. 190 - 200, http://dx.doi.org/10.1016/j.ejca.2021.06.024

Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL, 2021, 'Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial', Gynecologic Oncology, 162, pp. 375 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.05.031

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y

Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL, 2021, 'Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis', Cancer, 127, pp. 2432 - 2441, http://dx.doi.org/10.1002/cncr.33517

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Kurtz JE; Gebski V; Sukhin V; Carey M; Kong I; Glasspool RM; Berek JS; de Paiva Batista M; Hall M; Kim JW; Yeoshoua E; Fujiwara N; Nam BH; Polleis S; Lee JY; Strojna A; Farrelly L; Schwameis R; Fossati R; Darlington AS; Lai CH; Wright AA; Rosenblat O; Harter P; Roxburgh P; Chowdhury RR; Chang TC; Paoletti X; Friedlander M, 2021, 'Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee', Gynecologic Oncology, 161, pp. 502 - 507, http://dx.doi.org/10.1016/j.ygyno.2021.02.018

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E; Byrski T; Pautier P; Harter P; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Selle F; Ray-Coquard I; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Yunokawa M; Medioni J; Pécuchet N; Dubot C; De La Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Banerjee S; Cosin J; Hoffman J; Plante M; Covens A; Joly F; Hirte H; Amit A; Matsumoto K; Tjulandin S; Hoon Kim J; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez De Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I; Sikorska M; Słowińska A; Rogowski W; Bidziński M; Śpiewankiewicz B, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 620 - 631, http://dx.doi.org/10.1016/S1470-2045(21)00073-5

Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P, 2021, 'Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial', The Lancet Oncology, 22, pp. 632 - 642, http://dx.doi.org/10.1016/S1470-2045(21)00098-X

Francis KE; Gebski V; Lord SJ; Friedlander M; Pujade-Lauraine E; Lee CK, 2021, 'Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting', European Journal of Cancer, 148, pp. 251 - 259, http://dx.doi.org/10.1016/j.ejca.2021.02.006

Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML, 2021, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer', Gynecologic Oncology, 161, pp. 374 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.02.002

Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB, 2021, 'Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response', Oncologist, 26, pp. 366 - 374, http://dx.doi.org/10.1002/onco.13697

Evans DG; Phillips KA; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA; Blasinska-Morawiec M; Chosia M; Drosik K; Gozdecka-Grodecka S; Gozdz S; Grzybowska E; Jeziorski A; Karczewska A; Kordek R; Synowiec A; Kozak-Klonowska B; Lamperska K; Lange D; Mackiewicz A; Mitus JW; Niepsuj S; Oszurek O; Gugala K; Morawiec Z; Mierzwa T; Posmyk M; Rys J; Szczylik C; Ucinski M; Urbanski K; Wasko B; Wandzel P; Friedlander M; McLachlan SA; Nesci S; Picken S; O’Connor S; Stanhope L; Eisen A; Sweet K; Kim R; Foulkes W; Moller P; Neuhausen S; Cullinane C; Eng C; Ainsworth P; Couch F; Singer C; Karlan B; McKinnon W; Wood M, 2021, 'Survival from breast cancer in women with a BRCA2 mutation by treatment', British Journal of Cancer, 124, pp. 1524 - 1532, http://dx.doi.org/10.1038/s41416-020-01164-1

Ledermann JA; Embleton-Thirsk AC; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Oza A; Vaughan M; Friedlander M; González-Martín A; Deane E; Popoola B; Farrelly L; Swart AM; Kaplan RS; Parmar MKB, 2021, 'Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial', ESMO Open, 6, http://dx.doi.org/10.1016/j.esmoop.2020.100043

MacDonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper JL; Friedlander ML; Emery J; Phillips KA, 2021, 'Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkaa110

Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan SA; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips KA, 2021, 'Breast cancer chemoprevention: Use and views of australian women and their clinicians', Cancer Prevention Research, 14, pp. 131 - 144, http://dx.doi.org/10.1158/1940-6207.CAPR-20-0369

Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189

Al Ramadhani RM; Nagle CM; Ibiebele TI; Grant P; Friedlander M; De Fazio A; Webb PM, 2021, 'Pre- And post-diagnosis diet quality and ovarian cancer survival', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 229 - 232, http://dx.doi.org/10.1158/1055-9965.EPI-20-1036

Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; Chenevix-Trench G; Green A; Webb P; De Fazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N, 2021, 'Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses', Modern Pathology, 34, pp. 194 - 206, http://dx.doi.org/10.1038/s41379-020-0618-9

Lux MP; Ciani O; Dunlop WCN; Ferris A; Friedlander M, 2021, 'The impasse on overall survival in oncology reimbursement decision-making: How can we resolve this?', Cancer Management and Research, 13, pp. 8457 - 8471, http://dx.doi.org/10.2147/CMAR.S328058

Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis', JCO Precision Oncology, 5, pp. 1151 - 1159, http://dx.doi.org/10.1200/PO.21.00108

Hansen JM; Nagle CM; Ibiebele TI; Grant PT; Obermair A; Friedlander ML; DeFazio A; Webb PM, 2020, 'A healthy lifestyle and survival among women with ovarian cancer', International Journal of Cancer, 147, pp. 3361 - 3369, http://dx.doi.org/10.1002/ijc.33155

Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann J; Penson R; Oza A; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Lord SJ; Kim SI; Lee JY; Colombo N; Park-Simon TW; Fujiwara K; Sonke G; Vergote I; Kim JW; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy', European Journal of Cancer, 139, pp. 59 - 67, http://dx.doi.org/10.1016/j.ejca.2020.08.021

DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN, 2020, 'Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial', Journal of Clinical Oncology, 38, pp. 3528 - 3537, http://dx.doi.org/10.1200/JCO.20.00799

Macdonald C; Mazza D; Hunter M; Keogh LA; Milne R; Hickey M; Saunders C; McLachlan SA; Friedlander M; Hopper J; Emery J; Jones S; Phillips KA, 2020, 'Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians', European Journal of Cancer, 138, pp. S8, http://dx.doi.org/10.1016/S0959-8049(20)30547-5

Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; Collonge-Rame MA; Delnatte C; Faivre L; Giraud S; Lasset C; Mari V; Mebirouk N; Mouret-Fourme E; Schuster H; Stoppa-Lyonnet D; Antoniou A; Cook J; Davidson R; Easton D; Eeles R; Evans DG; Frost D; Hanson H; Izatt L; Ong KR; Side L; O’Shaughnessy-Kirwan A; Tischkowitz M; Walker L; Daly MB; de la Hoya M; de Putter R; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Ejlertsen B; Engel C; Foretova L; Fostira F; Friedlander M; Friedman E; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Glendon G; Godwin AK; Goldgar DE, 2020, 'Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants', Genetics in Medicine, 22, pp. 1653 - 1666, http://dx.doi.org/10.1038/s41436-020-0862-x

Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK, 2020, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 21, pp. 1269 - 1282, http://dx.doi.org/10.1016/S1470-2045(20)30447-2

Beesley VL; Webber K; Nagle CM; DeFazio A; Obermair A; Williams M; Friedlander M; Webb PM, 2020, 'When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer', Gynecologic Oncology, 159, pp. 179 - 186, http://dx.doi.org/10.1016/j.ygyno.2020.07.029

Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK, 2020, 'Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis', JAMA Network Open, 3, pp. E2011809, http://dx.doi.org/10.1001/jamanetworkopen.2020.11809

Ross TL; DeFazio A; Friedlander M; Grant P; Nagle CM; Williams M; Webb PM; Beesley VL, 2020, 'Insomnia and its association with quality of life in women with ovarian cancer', Gynecologic Oncology, 158, pp. 760 - 768, http://dx.doi.org/10.1016/j.ygyno.2020.06.500

Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; Bowtell DD; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier,a A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2020, 'Prognostic gene expression signature for high-grade serous ovarian cancer', Annals of Oncology, 31, pp. 1240 - 1250, http://dx.doi.org/10.1016/j.annonc.2020.05.019

Ngoi NYL; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DGZ; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DSP, 2020, 'A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)', International Journal of Gynecological Cancer, 30, pp. 1239 - 1242, http://dx.doi.org/10.1136/ijgc-2020-001604

Back to profile page